GSK3B and breast carcinoma: GSK3β inactivation stabilizes β-catenin expression, induces its translocation to the nucleus, upregulates the downstream target CCND1 gene (encoding cyclin D1), and promotes breast cancer stem cell (BCSC) function and mammary tumor development9,10.